kinesin family member 1BGenealiases: CMT2 · CMT2A · CMT2A1 · HMSNII · KLP · NBLST1
Q-omics provides the consensus-scored KIF1B profile across patient tissues and cancer cell-line models. KIF1B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KIF1B is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, KIF1B RNA expression shows 20,970 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, LIHC, and ACC as cancer lineages where KIF1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIF1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIF1B survival associations across molecular data types. KIF1B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (12) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIF1B RNA expression–survival associations across cancer types. High KIF1B expression shows unfavorable associations in BLCA, ACC, LUSC and UVM, but favorable associations in KIRC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KIF1B RNA expression.
This table summarizes KIF1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KIF1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIF1B shows lower tumor expression in BRCA, COAD, UCEC and KICH and higher tumor expression in LIHC and LUSC. The LIHC box plot shows higher KIF1B RNA expression in tumor versus normal tissue (log2 FC = +0.688, t-test p < 0.001).
This table shows molecular features associated with KIF1B in patient tissues and cancer cell lines. In patient samples, KIF1B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KIF1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
